Coherus BioSciences, Inc. , today announced that it has filed four petitions for Inter Partes Review in the United States Patent and Trademark Office seeking invalidation of AbbVie’s U.S. Patent 9,085,619 .  The ‘619 patent is generally directed to formulations of adalimumab that do not contain a buffer.